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Abstract: BACKGROUND AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), riton-
avir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin
has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent
subgenotype worldwide. We evaluated whether ribavirin is necessary for ABT-450, ritonavir, ombitasvir,
and dasabuvir to produce high rates of sustained virologic response (SVR) in these patients. METHODS
We performed a multicenter, open-label, phase 3 trial of 179 patients with HCV genotype 1b infection,
without cirrhosis, previously treated with peginterferon and ribavirin. Patients were assigned randomly
(1:1) to groups given ABT-450, ritonavir, ombitasvir, and dasabuvir, with ribavirin (group 1) or without
(group 2) for 12 weeks. The primary end point was SVR 12 weeks after treatment (SVR12). We assessed
the noninferiority of this regimen to the rate of response reported (64%) for a similar population treated
with telaprevir, peginterferon, and ribavirin. RESULTS Groups 1 and 2 each had high rates of SVR12,
which were noninferior to the reported rate of response to the combination of telaprevir, peginterferon,
and ribavirin (group 1: 96.6%; 95% confidence interval, 92.8%-100%; and group 2: 100%; 95% confi-
dence interval, 95.9%-100%). The rate of response in group 2 was noninferior to that of group 1. No
virologic failure occurred during the study. Two patients (1.1%) discontinued the study owing to adverse
events, both in group 1. The most common adverse events in groups 1 and 2 were fatigue (31.9% vs
15.8%) and headache (24.2% vs 23.2%), respectively. Decreases in hemoglobin level to less than the
lower limit of normal were more frequent in group 1 (42.0% vs 5.5% in group 2; P < .001), although
only 2 patients had hemoglobin levels less than 10 g/dL. CONCLUSIONS The interferon-free regimen of
ABT-450, ritonavir, ombitasvir, and dasabuvir, with or without ribavirin, produces a high rate of SVR12
in treatment-experienced patients with HCV genotype 1b infection. Both regimens are well tolerated, as
shown by the low rate of discontinuations and generally mild adverse events. ClinicalTrials.gov number:
NCT01674725.
DOI: 10.1053/j.gastro.2014.04.045
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ABSTRACT (300 260 word limit, current count 297260) 68 
Background & Aims: The interferon-free regimen of ABT-450 (protease inhibitor), ritonavir (r), 69 
ombitasvir ABT-267 (NS5A inhibitor), ABTdasabuvir-333 (nonnucleoside polymerase inhibitor), and 70 
ribavirin (RBV) has shown efficacy in a phase 2 study in patients infected with HCV genotype (GT)1b, the 71 
most prevalent subgenotype worldwide. We evaluated whether RBV is necessary with ABT-450/r/ABT-72 
267ombitasvir, and ABT-333dasabuvir to achieve high sustained virologic response (SVR) rates in this 73 
populationGT1b-infected patients. 74 
Methods: PEARL-II was a multicenter, open-label phase 3 trial evaluating 179 75 
treatmentpeginterferon/RBV-experienced, non-cirrhotic HCV GT1b-infected patients randomized 1:1 to 76 
ABT-450/r/ABT-267ombitasvir (150mg/100mg/25mg once daily) and, ABT-333dasabuvir  (250mg twice 77 
daily) with weight-based RBV (Group 1RBV) or without (Group 2) for 12 weeks. The primary endpoint was 78 
SVR 12 weeks post-treatment (SVR12). Noninferiority to the historical response rate in a similar 79 
population treated with telaprevir plus peginterferon/RBV (64%) was assessed.  80 
FindingsResults: High rates of SVR12 and non-inferiority to historical rates were achieved whether with 81 
(96.6% [95% CI, 92.8–100]) and without RBV was included in the regimen or not (96·6% [95% CI, 92·8 – 82 
100] and 100% [95% CI, 95.9 – 100]) for Group 1RBV and Group 2, respectively). Additionally, Group 2 was 83 
noninferior to Group 1RBV. No virologic failure occurred during the study. Two (1.1%) patients 84 
discontinued the study due to adverse events, both in Group 1RBV. The most common adverse events in 85 
Groups 1RBV and 2 were fatigue (31.9% vs. 15.8%) and headache (24.2% vs. 23.2%), respectively. 86 
Hemoglobin decreases to below the lower limit of normal were statistically more frequent in Group 1RBV 87 
(42.0% vs. 5.5%, P < 0.001), although only two patients experienced hemoglobin <declines to below 10 88 
g/dL.  89 
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Conclusions: The IFN-free regimen of ABT-450/r/ABT-267ombitasvir, and ABT-333dasabuvir, with or 90 
without RBV, achieved high SVR12 rates in HCV GT1b-infected treatment-experienced patients. Both 91 
regimens were well tolerated,  as evidenced by the low rate of discontinuations and generally mild 92 
adverse events.  93 
Funding: AbbVie; ClinicalTrials.gov number, NCT01674725 94 
Keywords: HCVRibavirin-free,; direct-acting antiviralinterferon experienced,; interferon-free therapy,; 95 
sustained virologic response96 
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INTRODUCTION 97 
Untreated chronic hepatitis C virus (HCV) infection is a leading cause of liver damage, cirrhosis, and 98 
hepatocellular carcinoma.1 Prevalence of HCV infection is estimated at 3% worldwide and results in 99 
approximately 350 000 deaths annually.2, 3 Genotype 1 accounts for approximately 70% of all HCV 100 
infections and subgenotype 1b is most predominant in Europe and Eastern Asia. Approved direct-acting 101 
antiviral agents (DAAs), telaprevir, boceprevir, sofosbuvir, and simeprevir, given with pegylated-102 
interferon (pegIFN) and ribavirin (RBV) have reported sustained virologic response (SVR) rates of 67% to 103 
89% in HCV genotype 1-infected patients. Response rates with DAA regimens are generally lower in 104 
patients who have failed previous pegIFN-containing treatment regimens than in treatment-naïve 105 
patients, and noticeably lower among prior null responders.4-8 Additionally, the toxicity of pegIFN and 106 
long duration of therapy (up to 48 weeks with some regimens) are a hardship for patients.9 Notably, 107 
pegIFN-based treatment regimens have a well-documented adverse event (AE) profiles including 108 
influenza-like symptoms and depression that have led to unfavorable discontinuation rates in clinical 109 
trials,6, 9-12 while RBV also has associated side effects including teratogenicity, hemolytic anemia, and 110 
rash.13, 14 111 
All-oral and interferon-free HCV treatment regimens with DAAs provide wider treatment access to 112 
patients in need with chronic liver disease. ABT-450 is an NS3/4A protease inhibitor with in vitro 113 
nanomolar antiviral activity and is co-dosed with the CYP3A4 inhibitor, ritonavir (r), which significantly 114 
increases peak and trough drug concentrations enabling once-daily dosing.15 The multi-targeted, all-oral 115 
combination of ABT-450/r, ABT-267ombitasvir (formerly ABT-267), an HCV NS5A inhibitor with 116 
pangenotypic picomolar antiviral activity,16 and ABT-333dasabuvir (formerly ABT-333), an HCV NS5B 117 
RNA nonnucleoside polymerase inhibitor, with RBV has shown in a phase 2b trial to achieve high rates of 118 
sustained virologic response 12 weeks post-treatment (SVR12) in treatment-naïve and -experienced 119 
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genotype 1-infected patients. With this regimen, a 93% SVR12 rate was achieved in genotype 1-infected 120 
non-cirrhotic patients with prior null response to pegIFN/RBV, and 100% SVR12 in the genotype 1b 121 
patient subset.17 These high response rates in prior null responders, considered difficult to treat, are 122 
promising and require confirmation in a large phase 3 trial. While ABT-450/r/ABT267 ombitasvir and 123 
ABT-333dasabuvir with RBV may achieve high SVR12 rates, determining the benefit gained by including 124 
RBV in the regimen has not been assessed in these patients. This phase 3 study (PEARL-II) evaluated the 125 
efficacy and safety of 12-week treatment with ABT-450/r/ABT267 ombitasvir+ and ABT-333dasabuvir 126 
with or without RBV exclusively in non-cirrhotic pegIFN/RBV treatment-experienced HCV genotype 1b-127 
infected patients. 128 
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METHODS 129 
Patients. Adults were 18 to 70 years old at the time of screening from 43 sites in Austria, Belgium, Italy, 130 
The Netherlands, Portugal, Puerto Rico, Sweden, Switzerland, Turkey, and the United States. Patients 131 
were required to have documentation that they previously failed treatment with pegIFN/RBV. Eligible 132 
patients were required to be non-cirrhotic with chronic HCV genotype 1b-infection for at least 6 months 133 
with an HCV RNA level > 10 000 IU/mL at screening. Patients were excluded if they had evidence of co-134 
infection with any HCV genotype other than 1b or tested positive for Hepatitis B surface antigen or anti-135 
HIV antibody at screening. Detailed eligibility criteria are provided in the Supplementary Appendix. 136 
Study design. Patients were stratified by type of previous non-response to pegIFN/RBV treatment (null 137 
responders, partial responders, and relapsers) and randomized 1:1 to receive the 12-week regimen of 138 
ABT-450/r/ABT-267ombitasvir (150mg/100mg/25mg once daily) and ABT-333dasabuvir (250mg twice 139 
daily) with either weight-based RBV dosed twice daily (1000mg daily if body weight was less than 75kg, 140 
1200mg daily if body weight was greater than or equal to 75kg) for Group 1RBV or without RBV for Group 141 
2. After 12 weeks of treatment, patients were followed for 48 additional weeks. Additional details on 142 
study design are in the Supplementary Appendix.  143 
The study was conducted in accordance with the International Conference of Harmonisation guidelines, 144 
applicable regulations, and guidelines governing clinical study conduct and ethical principles that have 145 
their origin in the Declaration of Helsinki (ClinicalTrials.gov number, NCT01674725). All patients 146 
provided written informed consent.  147 
Safety Assessments. Adverse event assessments were reported from the time of study drug 148 
administration until 30 days after last dose and were judged mild, moderate, or severe; clinical 149 
laboratory testing was performed at each study visit. Serious AEs were collected throughout the study. 150 
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Efficacy Endpoints. Plasma samples were collected at screening and each study visit and HCV RNA levels 151 
determined using the Roche COBAS TaqMan real-time RT-PCR assay v2.0 at a central lab. A fixed-152 
sequence testing procedure was used to control Type I error at 0.05. The primary efficacy endpoint was 153 
noninferiority of the SVR12 rates (assessed by HCV RNA < 25 IU/mL) of Group 2 and Group 1RBV to the 154 
historical SVR12 rate for telaprevir plus pegIFN/RBV in HCV genotype 1b-infected patients who were 155 
relapsers, partial responders, or null-responders to previous pegIFN/RBV treatment,4 adjusted for non-156 
cirrhotic patients in this study. Group 1RBV and Group 2 noninferiority could be claimed if the SVR12 lower 157 
bound of the 95% confidence interval (CI) was greater than the upper bound of the CI for the historical 158 
rate minus a 10.5% noninferiority margin (64%). Further details of historical noninferiority calculations 159 
are provided in the Supplementary Appendix. Secondary efficacy endpoints in the fixed-sequence 160 
included the following: (1) comparison of the percentage of patients with a decrease in hemoglobin to 161 
below the lower limit of normal (LLN) at the end of treatment; (2) superiority of Group 1RBV and Group 2 162 
to the historical rate for telaprevir plus pegIFN/RBV (75%); and (3) noninferiority of Group 2 to Group 163 
1RBV using a 10.5% noninferiority margin for the SVR12 difference. The percentage of patients with on-164 
treatment virologic failure and post-treatment relapse was also assessed.  165 
Virologic failure criteria. Virologic failure leading to discontinuation of study drug was determined if the 166 
following criteria occurred: confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV 167 
RNA measurements greater than 1 log10 IU/mL above nadir) at any point during treatment; failure to 168 
achieve HCV RNA < 25 IU/mL by Week 6; and confirmed HCV RNA ≥ 25 IU/mL in two consecutive 169 
measurements at any point during treatment after HCV RNA < 25 IU/mL. Post-treatment relapse was 170 
confirmed in patients with HCV RNA < 25 IU/mL at the end of treatment and subsequent RNA ≥ 25 171 
IU/mL in two consecutive measurements.  172 
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Statistical Analyses. Efficacy analyses were performed using the intent-to-treat population defined as all 173 
randomized HCV genotype 1b-infected patients who received at least one dose of coformulated ABT-174 
450/r/ABT-267ombitasvir. The safety population included all patients that received at least one dose of 175 
study drug. A population of 90 patients per treatment arm was calculated to provide greater than 90% 176 
power to achieve noninferiority of the active regimen to the historical threshold (64%). 177 
SAS software for the UNIX operating system was used for all analyses. All statistical tests and all 178 
confidence intervals were two-sided with a significance level of 0.05. 179 
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RESULTS 180 
Baseline Patient Demographics and Characteristics. Patient screening began 14 August 2012 and the last 181 
SVR12 data were collected 16 January 2014. Of 324 patients screened, 187 were randomized and 186 182 
received study drug (91 Group 1RBV, 95 Group 2) (Figure 1). Null-responders, partial-responders, and 183 
relapsers to previous pegIFN/RBV treatment made up 34.9%, 28.5%, and 36.6% of the study population, 184 
respectively, evenly stratified between treatment arms (Table 1). Reasons for screen failures are 185 
provided in the Supplemental Appendix. Seven randomized patients, three in Group 1RBV and four in 186 
Group 2 were not included in the intent-to-treat efficacy population. Of these, six patients were enrolled 187 
prior to a protocol amendment and received non-coformulated ABT-450/r/ABT-267ombitasvir, 3 of 188 
whom were genotype 1a; a seventh patient’s HCV subgenotype was not determined.  189 
Efficacy. After 12 weeks of treatment, 96.6% (85/88; 95% CI, 92.8 – 100) of Group 1RBV and 100% (91/91; 190 
95% CI, 95.9 – 100) of Group 2 patients achieved SVR12 using the intent-to-treat population for both 191 
groups (Table 2). For the primary endpoint, SVR12 rates in both treatment groups were noninferior to 192 
the historical SVR rate for telaprevir plus pegIFN/RBV in comparable treatment-experienced patients. 193 
Both treatment groups were also superior to the historical rate. Noninferiority of Group 2 to Group 1RBV 194 
was met as the treatment difference in SVR12 rates was 3.4% (95% CI, -0.4 – 7.2). 195 
No patients from either treatment group experienced on-treatment virologic failure or post-treatment 196 
relapse. Of the three patients in Group 1RBV that did not achieve SVR12, two (2.3%) patients discontinued 197 
study drug due to AEs, and one patient was lost to follow-up after SVR4 (Table 3).  198 
Sustained virologic responses in both groups were not influenced by previous non-response, age, race, 199 
or IL28B genotype. Among Group 1RBV null-responders, partial-responders, and relapsers to previous 200 
pegIFN/RBV treatment, SVR12 rates were 93.5%, 96.0%, and 100%, respectively. Group 1RBV rates were 201 
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similarly high regardless of IL28B genotype (CC: 100%, CT: 96.4%, TT: 95.5%), or sex (male: 95.3%, 202 
female: 97.8%). Group 2 SVR12 rates were 100% in all subgroups.  203 
Lastly, the seven patients excluded from the efficacy subset due to receiving non-coformulated study 204 
drug, confirmed genotype 1a, or undetermined genotype all completed treatment and achieved SVR12. 205 
Safety. Treatment-emergent AEs (TEAE) were experienced by 79.1% of patients in Group 1RBV and 77.9% 206 
of patients in Group 2. Most TEAEs were mild with the most commonly reported events in Group 1RBV 207 
and Group 2 being fatigue (31.9% vs. 15.8%, P = 0.015), headache (24.2% vs. 23.2%, P = NS> 0.05), and 208 
nausea (20.9% vs. 6.3%, P = 0.005), respectively (Table 3). Patients in Group 1RBV also experienced 209 
statistically significantly more events of insomnia, anemia, rash, and increased blood bilirubin, all known 210 
to be associated with RBV use; no patient discontinued study drug due to these events.  211 
Overall, two (1.1%) patients discontinued treatment due to AEs, both in Group 1RBV. One patient 212 
experienced two serious AEs of pancreatitis that were considered by the investigator not to be study 213 
drug related. This patient had elevated amylase on Day 1 prior to receiving study drug; on Day 11, the 214 
patient reported abdominal pain and was hospitalized on Day 13, at which point study drugs were 215 
discontinued. The patient experienced another mild episode of pancreatitis on Day 31 that resolved by 216 
Day 36. Another patient reported anxiety, tachycardia, fever, and dyspnea on Day 36 that led to study 217 
discontinuation. Three other serious TEAEs included cellulitis, nephrolithiasis, and osteoarthritis; none 218 
were judged to be study drug-related. 219 
Hemoglobin levels below the LLN at end of treatment, a secondary endpoint, was experienced more 220 
often by patients in Group 1RBV compared to Group 2 (42.0% vs. 5.5%, respectively, P < 0.001), although 221 
clinically significant grade 2 hemoglobin declines to below 10 g/dL at the end of treatment occurred in 222 
only 2 (1.1%) of patients, both in Group 1RBV. No patient required a blood transfusion or erythropoietin. 223 
Elevations in total bilirubin greater than 2 x the upper limit of normal (ULN) were reported in 15.4% of 224 
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patients in Group 1RBV and 1.1% of patients in Group 2 (P < 0.001), with 8.8% of patients in Group 1RBV 225 
and 0% in Group 2 reporting greater than 3 x ULN. Mean levels of bilirubin were elevated at Week 1 in 226 
both groups, but bilirubin levels (predominantly indirect bilirubin) remained elevated throughout the 227 
treatment period only in Group 1RBV (Supplemental Figure S3). Five (5.5%) patients in Group 1RBV and 2 228 
(2.1%) patients in Group 2 reported hyperbilirubinaemia; three (3.3%) patients in Group 1RBV reported 229 
jaundice. One hyperbilirubinaemia and one jaundice event were moderate in severity and the remaining 230 
events were judged mild; none led to study drug discontinuation. Ribavirin dose modification occurred 231 
in five patients, three due to anemia, one due to hyperbilirubinaemia, and one was dose adjusted due to 232 
decrease in weight; all achieved SVR12. 233 
The percentage of patients with post-baseline alanine aminotransferase (ALT) levels greater than 3 x 234 
ULN was similarly low for both treatment groups. No patient experienced post-baseline ALT level greater 235 
than 5 x ULN. One patient in Group 2 had an aspartate aminotransferase (AST) level greater than 5 x 236 
ULN at a single time study visit, with all subsequent values normal. Twelve weeks of treatment with 237 
these regimens normalized liver enzymes in almost all patients with elevated baseline liver enzymes: 238 
96.9% (63/65) and 100% (66/66) of Group 1RBV and Group 2 patients, respectively, with high baseline 239 
ALT levels reached normal values following treatment; AST levels were normalized in 98.4% (60/61) and 240 
91.8% (56/61) of Group 1RBV and Group 2 patients, respectively. Median changes from baseline in 241 
aminotransferase values at final treatment visit were similar comparing treatment groups (ALT: -35.0 vs. 242 
-36.0 U/L; AST: -22.0 vs. -21.0 U/L for Group 1RBV and Group 2, respectively).243 
13 
 
PEARL-II Primary_Ms_Gastro_FinalDraft1  13 February 2015 
Word count- 28004342/30006000 words (including abstract, figure, tables, and references) 
DISCUSSION 244 
PEARL-II examined an all-oral, interferon-free regimen with or without RBV exclusively in pegIFN/RBV 245 
treatment-experienced, non-cirrhotic patients with HCV genotype 1b infection. The intent-to-treat SVR12 246 
rates of 96.6% to 100% in patients receiving the 12-week regimen of ABT-450/r/ABT-267ombitasvir and 247 
ABT-333dasabuvir with or without RBV, respectively, were superior to the historical rate of telaprevir 248 
plus pegIFN/RBV. The SVR12 rates of this multi-targeted regimen with RBV confirm results of the Phase 249 
2b AVIATOR study17 in prior null-responders, the most difficult to treat of pegIFN/RBV non-responders, 250 
and further expands efficacy conclusions to patients who were partial responders and relapsers to 251 
pegIFN/RBV treatment. In addition, PEARL-II demonstrated noninferiority of the RBV-free regimen to 252 
the RBV-containing regimen, supporting the use of ABT-450/r/ABT-267ombitasvir and ABT-333dasabuvir 253 
without RBV for 12 weeks in the treatment of HCV genotype 1b-infected pegIFN/RBV-experienced 254 
patients without cirrhosis. 255 
The TEAEs associated with either group in this 12-week regimen were generally mild and manageable. 256 
Overall, only two (1.1%) treated patients discontinued treatment due to AEs, and the five serious TEAEs 257 
reported in four patients were considered to be unrelated to study drug by the investigators. As 258 
expected, known RBV adverse events (fatigue, nausea, insomnia, rash, anemia, and increased bilirubin) 259 
were statistically more prevalent in Group1RBV, although frequency and severity appear reduced 260 
compared to when RBV is combined with pegIFN.7, 18 Hemoglobin declines were also more frequent in 261 
Group 1RBV although few (2.2%) reached clinical significance, and AEs leading to RBV dose reduction 262 
occurred in only four patients. Elevated bilirubin levels in Group 1RBV were predominantly due to indirect 263 
bilirubinemia, consistent with the hemolysis associated with RBV and the known effect of ABT-450 on 264 
the bilirubin transporter OATP1B1, though lack of bilirubin elevations in Group 2 suggest the 265 
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predominant cause was RBV-related hemolysis. Liver enzyme normalization was consistent with the high 266 
rate of virologic response. 267 
The SVR12 rates reported here compare favorably to published reports of other interferon-free regimens 268 
using the NS5B RNA polymerase inhibitor sofosbuvir in combination with NS5A inhibitors (daclatasvir or 269 
ledipasvir), or with an NS3/4A protease inhibitor (simeprevir). Combinations of sofosbuvir plus 270 
daclatasvir with or without RBV have shown greater than or equal to 95% SVR12 in 41 treatment-271 
experienced genotype 1 patients, of which only eight patients were genotype 1b.19 Similar SVR12 rates 272 
have been reported in treatment-experienced genotype 1 patients with sofosbuvir plus ledipasvir with 273 
(21/21, 100%) or without RBV (18/19, 95%), although only six genotype 1b patients were included.20 In 274 
13 genotype 1b-infected patients receiving the combination of simeprevir plus sofosbuvir with or 275 
without RBV, 100% SVR8 was reported.21 Together with the results from PEARL-II, these data support a 276 
multi-targeted approach to achieve SVR; however, no other studies have exclusively analyzed, nor had 277 
the statistical power to draw conclusions regarding efficacy, including the contribution of RBV, in 278 
treatment-experienced HCV genotype 1b patients as the PEARL-II study does.  279 
One of the strengths of the PEARL-II study includes its large sample size in genotype 1b-infected 280 
patients, the most prevalent subgenotype worldwide, including patients with previous null response and 281 
relapse to pegIFN/RBV treatment. Treatment-experienced genotype 1b-infected patients have not been 282 
extensively studied with currently approved or investigational IFN-free regimens, hence this large 283 
patient population represents a group with unmet need. Study limitations include the open label study 284 
design, the exclusion of patients with cirrhosis, HBV or HIV coinfection, and that these findings may be 285 
specific to genotype 1b-infected patients. However, this regimen is also being investigated in parallel 286 
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In conclusion, a 12-week regimen of ABT 450/r/ABT-267ombitasvir and ABT-333dasabuvir with or 289 
without RBV was generally well-tolerated in pegIFN/RBV treatment experienced, non-cirrhotic, HCV 290 
genotype 1b-infected adults, as evidenced by the low rate of treatment discontinuation and serious 291 
adverse events. Additionally, the regimen without RBV was associated with fewer adverse events of 292 
fatigue, nausea, insomnia, rash, and a lower rate of laboratory abnormalities including bilirubin 293 
elevation and hemoglobin decrease. Sustained virologic response rates of 96.6% and 100% were 294 
achieved, including 93.5% and 100% in the difficult to treat previous pegIFN/RBV null-responders, with 295 
or without RBV, respectively. Therefore, ABT-450/r/ABT-267ombitasvir and ABT-333dasabuvir without 296 
RBV is recommended sufficient to achieve optimal treatment efficacyfor treatment of HCV genotype 1b 297 
infection in this population.   298 
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Panel. 299 
Research in context  300 
SYSTEMATIC REVIEW 301 
In February 2014, we used Pubmed with the search “HCV” AND “Null responder”, which produced 12 302 
results. Among the results was a literature review published in 2013 highlighting the trial data of 303 
currently approved or investigative DAAs with or without peg/IFN.22 The literature review included data 304 
from seven protease inhibitors, three nucleoside inhibitors, four nonnucleoside inhibitors, and three 305 
NS5A inhibitors.  306 
INTERPRETATION 307 
Focusing specifically on the population investigated in PEARL-II, of the 11 cited studies (excluding 308 
publications with the regimen presented here), four included non-cirrhotic, treatment-experienced 309 
genotype 1-infected patients, and only three exclusively examined subgenotype 1b. In the four genotype 310 
1 studies, the sum of the patient population examined was 80; however, the sum of genotype 1b 311 
patients examined was only 38. Sustained virologic response rates in these patients were 83% (15/18) to 312 
100% (2/2) using asunaprevir plus pegIFN and daclatasvir23-25. The combination of sofosbuvir plus 313 
daclatasvir with or without RBV achieved SVR12 in 100% (8/8) genotype 1b-infected patients.19 314 
Importantly, all of these studies were with 24 weeks of treatment compared to the 12-week regimen we 315 
present. Additionally, only eight prior null responders with genotype 1b infection were receiving pegIFN-316 
free therapies. In comparison, the PEARL-II study was powered to specifically examine genotype 1b prior 317 
non-responders to pegIFN/RBV treatment with a multi-targeted 12-week treatment. Individual HCV 318 
treatment regimens vary in their efficacy to different genotypes, thus critically analysing each as we 319 
have done is of significant importance. The efficacy population of the PEARL-II study (N = 179) robustly 320 
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supports the SVR conclusions in this under-studied genotype 1b population that represents the most 321 
prevalent HCV infection worldwide. 322 
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Figure 1. Patient flow diagram.  398 
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Table 1. Baseline demographics and characteristics, n (%) 
Parameter 
Group 1RBV 
3-DAA + RBV 
(N = 91) 
Group 2 
3-DAA 
(N = 95) 
Sex, male 45 (49.5) 57 (60.0) 
Race   
White 84 (92.3) 86 (90.5) 
Black 3 (3.3) 6 (6.3) 
Ethnicity, Hispanic/Latino 4 (4.4) 2 (2.1) 
Geographic region   
North America 14 (15.4) 19 (20.0) 
Europe 77 (84.6) 76 (80.0) 
Age (years), mean (±SD) 54.2 ± 10.9 54.2 ± 10.5 
BMI (kg/m2), mean (±SD) 26.2 ± 4.1 27.5 ± 4.3 
IL28B genotype   
CC 10 (11.0) 7 (7.4) 
Non-CC 81 (89.0) 88 (92.6) 
HCV RNA (log10 IU/mL), mean (±SD) 6.56 ± 0.56 6.48 ± 0.53 
Previous pegIFN/RBV non-response   
Null responder 32 (35.2) 33 (34.7) 
Partial-responder 26 (28.6) 27 (28.4) 
Relapser 33 (36.3) 35 (36.8) 
Baseline fibrosis stage   
F0 – F1 64 (70.3) 61 (64.2) 
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F2 13 (14.3) 21 (22.1) 
F3 14 (15.4) 13 (13.7) 
Fibrosis scoring information is provided in the Supplemental Appendix. BMI, body mass index; pegIFN, 
pegylated interferon; RBV, ribavirin. 
  399 
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Table 2. Intent-to-treata virologic response, n/N (%) 
Parameter 
Group 1RBV 





SVR12 85/88 (96.6) 91/91 (100) 3.4 (-0.4, 7.2) 
Previous non-response 
Null responder 29/31 (93.5) 32/32 (100) 6.5 (-2.2, 15.1) 
Non/partial responder 24/25 (96.0) 26/26 (100) 4.0 (-3.7, 11.7) 
Relapser 32/32 (100) 33/33 (100) 0 (N/A) 
Sex 
Male 41/43 (95.3) 54/54 (100) 4.7 (-1.6, 10.9) 
Female 44/45 (97.8) 37/37 (100) 2.2 (-2.1, 6.5) 
Race 
Black 3/3 (100) 5/5 (100) 0 (N/A) 
Non-black 82/85 (96.5) 86/86 (100) 3.5 (-0.4, 7.5) 
IL28B genotype 
CC 10/10 (100) 7/7 (100) 0 (N/A) 
CT 54/56 (96.4) 64/64 (100) 3.6 (-1.3, 8.4) 
TT 21/22 (95.5) 20/20 (100) 4.5 (-4.2, 13.2) 
aIntent-to-treat genotype 1b efficacy population includes all patients with subgenotype 1b infection who 
were assigned to and treated with ABT-450/r/ABT-267ombitasvir co-formulated drug. 
DAA, direct acting antiviral; RBV, ribavirin; SVR12, 12-week sustained virologic response. 
  400 
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Table 3. Patients Reporting TEAEs, n (%) 
Parameter 
Group 1RBV 
3-DAA + RBV 
(N = 91) 
Group 2 
3-DAA 
(N = 95) P value 
Any TEAE 72 (79.1) 74 (77.9)  
Any severe TEAE 0 (0) 1 (1.1)  
Any serious TEAE 2 (2.2) 2 (2.1)  
TEAE leading to discontinuation 2 (2.2) 0 (0)  
Common TEAEsa 
Fatigue 29 (31.9) 15 (15.8) 0.015 
Headache 22 (24.2) 22 (23.2)  
Nausea 19 (20.9) 6 (6.3) 0.005 
Insomnia 13 (14.3) 3 (3.2) 0.008 
Pruritus 13 (14.3) 8 (8.4)  
Diarrhea 12 (13.2) 12 (12.6)  
Asthenia 11 (12.1) 7 (7.4)  
Anemia 10 (11.0) 0 (0) < 0.001 
Blood bilirubin increased 8 (8.8) 0 (0) 0.003 
Rash 8 (8.8) 1 (1.1) 0.017 
Chemistry and Hematologic values of interest during treatment 
Hemoglobin below LLN at end of treatmentb 37 (42.0) 5 (5.5) < 0.001 
Total bilirubin > 3X ULN 8 (8.8) 0 (0) 0.003 
ALT > 5X ULN 0 (0) 0 (0)  
AST > 5X ULN 0 (0) 1 (1.1)  
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aInvestigator-reported TEAEs present in ≥ 10 % of either treatment group or with a statistically 
significant difference between treatment groups. 
bN’s = 88 and 91 for Group 1RBV and Group 2, respectively, using the intent-to-treat genotype 1b efficacy 
population. 
TEAE, treatment-emergent adverse event; DAA, direct acting antiviral; RBV, ribavirin; LLN, lower limit of 
normal; ULN, upper limit of normal; ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
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